MedTrace Logo

Subjects Through the Application of the Mindera Kit Part 2

NCT04904315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-05-27

No results posted yet for this study

Summary

A 16 week study to examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects.

Conditions

Interventions

OTHER

Mindera Kit

The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.

Sponsors & Collaborators

  • Mindera Health

    lead INDUSTRY

Principal Investigators

  • Toby Dickerson · CSO

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-01-01
Completion
2022-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04904315 on ClinicalTrials.gov